AR077908A1 - Compuestos de oxadiazol como moduladores de s1p - Google Patents
Compuestos de oxadiazol como moduladores de s1pInfo
- Publication number
- AR077908A1 AR077908A1 ARP100103076A ARP100103076A AR077908A1 AR 077908 A1 AR077908 A1 AR 077908A1 AR P100103076 A ARP100103076 A AR P100103076A AR P100103076 A ARP100103076 A AR P100103076A AR 077908 A1 AR077908 A1 AR 077908A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- alkyl
- phenyl
- cyclohexyl
- optionally
- Prior art date
Links
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical class C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 title 1
- -1 2,3-dihydroisoindolyl Chemical group 0.000 abstract 7
- 125000000217 alkyl group Chemical group 0.000 abstract 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 6
- 150000001875 compounds Chemical class 0.000 abstract 5
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 4
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 abstract 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 125000000842 isoxazolyl group Chemical group 0.000 abstract 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 abstract 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 abstract 2
- 125000000335 thiazolyl group Chemical group 0.000 abstract 2
- 125000006526 (C1-C2) alkyl group Chemical group 0.000 abstract 1
- 125000004605 1,2,3,4-tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 abstract 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 108091006027 G proteins Proteins 0.000 abstract 1
- 102000030782 GTP binding Human genes 0.000 abstract 1
- 108091000058 GTP-Binding Proteins 0.000 abstract 1
- 206010062016 Immunosuppression Diseases 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000002541 furyl group Chemical group 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 125000002883 imidazolyl group Chemical group 0.000 abstract 1
- 230000001506 immunosuppresive effect Effects 0.000 abstract 1
- 125000001041 indolyl group Chemical group 0.000 abstract 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000002757 morpholinyl group Chemical group 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 150000004866 oxadiazoles Chemical class 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000004193 piperazinyl group Chemical group 0.000 abstract 1
- 125000003386 piperidinyl group Chemical group 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 125000003373 pyrazinyl group Chemical group 0.000 abstract 1
- 125000003226 pyrazolyl group Chemical group 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 abstract 1
- 125000000168 pyrrolyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 1
- 125000005887 tetrahydrobenzofuranyl group Chemical group 0.000 abstract 1
- 125000001544 thienyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Compuestos de oxadiazol, composiciones farmacéuticas que contienen dichos compuestos y uso de dichos compuestos o de dichas composiciones como agonistas o antagonistas de los receptores unidos a la proteína G de la familia S1P, para tratar enfermedades asociadas con la modulacion de la actividad de los receptores de la S1P, particularmente al proveer un efecto de inmunosupresion beneficioso. Reivindicacion 1: Un compuesto caracterizado porque es de formula (1) sales aceptables farmacéuticamente, metabolitos biologicamente activos, solvatos, hidratos, prodrogas, racematos, enantiomeros o estereoisomeros del mismo, donde L es una union o alquilo C1-3 opcionalmente sustituido; R1 es -C(O)-NH-fenilo, -NH-C(O)-furanilo, -NH-S(O)2-fenilo opcionalmente sustituido, -O-alquilo C1-3 opcionalmente sustituido, -S-alquilo C1-3 opcionalmente sustituido, alquilo C2-6 opcionalmente sustituido, amino opcionalmente sustituido, cicloalquilo C3-6 opcionalmente sustituido, -(CH2)alquilo C3, tetrahidrobenzofuranilo opcionalmente sustituido, furanilo opcionalmente sustituido, tetrahidrofuranilo opcionalmente sustituido, 2,3-dihidroisoindolilo opcionalmente sustituido, isoindolinilo opcionalmente sustituido, imidazolilo opcionalmente sustituido, 5,6-dihidro imidazo[1,2-a]pirazinilo opcionalmente sustituido, imidazo[1,2-a]pirazinilo opcionalmente sustituido, indolilo opcionalmente sustituido, isoxazolilo opcionalmente sustituido, morfolinilo opcionalmente sustituido, naftilo opcionalmente sustituido, fenilo opcionalmente sustituido, -O-CH2-fenilo opcionalmente sustituido, -O-fenilo opcionalmente sustituido, -O-fenilo opcionalmente sustituido, piperidinilo opcionalmente sustituido, pirazolilo opcionalmente sustituido, piridinilo opcionalmente sustituido, pirimidinilo opcionalmente sustituido, pirrolidinilo opcionalmente sustituido, 1,2,3,4-tetrahidroisoquinolinilo opcionalmente sustituido, quinolinilo opcionalmente sustituido, 3,4-dihidroquinolinilo opcionalmente sustituido, 3,4-dihidroisoquinolinilo opcionalmente sustituido, 5,6,7,8-tetrahidroimidazo[1,2-a]pirazinilo opcionalmente sustituido, pirrolilo opcionalmente sustituido, pirrolo[2,3-b]piridinilo opcionalmente sustituido, quinolinilo opcionalmente sustituido, tiazolilo opcionalmente sustituido o tienilo opcionalmente sustituido; R2 es Br, Cl, CF3, CN, o -O-alquilo C1-2; R3 es alquilo C3-8 opcionalmente sustituido, alquilo C2-6deuterado, alquenilo C4-5, alquinilo C4-5, cicloalquilo C3-6 opcionalmente sustituido, alquilo C2-3 opcionalmente sustituido-O-alquilo C1-3 opcionalmente sustituido, alquilo C1-3 opcionalmente sustituido-imidazolilo, alquilo C1-3opcionalmente sustituido-morfolinilo, alquilo C1-3 opcionalmente sustituido-fenilo opcionalmente sustituido, alquilo C1-3 opcionalmente sustituido-piperazinilo opcionalmente sustituido, alquilo C1-3 opcionalmente sustituido-pirrolidinilo, alquilo C1-3 opcionalmente sustituido-piperidinilo, alquilo C1-3 opcionalmente sustituido-tienilo, tetrahidrofuranilo o tiazolilo opcionalmente sustituido; y R6 es H; con las siguientes condiciones R1 no está sustituido con ciclohexilo opcionalmente sustituido, -C(O)ciclohexilo o -NH-ciclohexilo; cuando L es alquilo C1-3, R1 no es isoxazolilo opcionalmente sustituido; cuando R3 es (C1)alquilo opcionalmente sustituido, L-R1 no es ciclohexilo o -CH2-ciclohexilo; y con la condicion de que el compuesto no sea un compuesto de formula (2) o (3).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26767909P | 2009-12-08 | 2009-12-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR077908A1 true AR077908A1 (es) | 2011-09-28 |
Family
ID=44145850
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100103076A AR077908A1 (es) | 2009-12-08 | 2010-08-23 | Compuestos de oxadiazol como moduladores de s1p |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP2509424A4 (es) |
| JP (1) | JP2013512951A (es) |
| CN (1) | CN102762102A (es) |
| AR (1) | AR077908A1 (es) |
| CA (1) | CA2783851A1 (es) |
| MX (1) | MX2012006667A (es) |
| TW (1) | TW201120016A (es) |
| UY (1) | UY32853A (es) |
| WO (1) | WO2011071570A1 (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2184989B1 (en) | 2007-08-13 | 2015-05-06 | Monsanto Technology LLC | Compositions and methods for controlling nematodes |
| AU2012304661A1 (en) | 2011-09-08 | 2014-04-03 | Allergan, Inc. | 3-(4-(5-phenyl-1,2,4-oxadiazol-3-yl)phenoxy)propan-2-ol derivatives as sphingosine-1 phosphate receptors modulators |
| ES2649475T3 (es) | 2013-03-15 | 2018-01-12 | Idorsia Pharmaceuticals Ltd | Derivados de piridin-4-ilo |
| US9828351B2 (en) * | 2014-06-26 | 2017-11-28 | Monash University | Enzyme interacting agents |
| US12209072B2 (en) | 2018-09-18 | 2025-01-28 | Bristol-Myers Squibb Company | Cyclopentyl acids as LPA antagonists |
| CN112702998A (zh) * | 2018-09-18 | 2021-04-23 | 百时美施贵宝公司 | 作为lpa拮抗剂的环庚酸 |
| ES2941774T3 (es) | 2018-09-18 | 2023-05-25 | Bristol Myers Squibb Co | Acidos oxabiciclo como antagonistas de LPA |
| CN109369620B (zh) * | 2018-12-22 | 2020-04-14 | 山东大学 | 吡啶类化合物及其制备方法与抗胃癌应用 |
| CN109776443B (zh) * | 2019-03-25 | 2022-09-27 | 上海万巷制药有限公司 | 一种具有抗氧化作用的噁二唑类化合物及其制备方法 |
| CN114728927B (zh) | 2019-11-19 | 2025-08-29 | 莫达戈有限公司 | 用于诊断、治疗和预防与α-突触核蛋白的聚集相关的疾病的化合物 |
| UY38964A (es) | 2019-11-25 | 2021-06-30 | Novartis Ag | Derivados de 1,2,4-oxadiazol como agonistas del receptor hepático x, sus usos y métodos relacionados referencia cruzada a solicitudes relacionadas |
| CN115260173B (zh) * | 2021-04-30 | 2024-08-30 | 厦门宝太生物科技股份有限公司 | 环戊烷并吲哚类支链酸衍生物及其制备方法和应用 |
| CN113662938B (zh) * | 2021-09-26 | 2022-08-16 | 广西科技大学 | 一种胺类衍生物在制备抗肿瘤药物组合物中的应用 |
| WO2023118253A1 (en) * | 2021-12-23 | 2023-06-29 | Chiesi Farmaceutici S.P.A. | Cyclohexane acid derivatives as lpa receptor inhibitors |
| EP4649080A1 (en) * | 2023-01-13 | 2025-11-19 | Oppilan Pharma Ltd. | Preparation of an s1p receptor modulator |
| CN116444454B (zh) * | 2023-06-16 | 2023-09-12 | 中国医学科学院医药生物技术研究所 | N-羟基脒衍生物及制备方法和应用、肿瘤免疫治疗药物 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI404706B (zh) * | 2006-01-11 | 2013-08-11 | Actelion Pharmaceuticals Ltd | 新穎噻吩衍生物 |
| BRPI0711358A2 (pt) * | 2006-05-09 | 2011-09-27 | Pfizer Prod Inc | derivados do ácido cicloalquilamino e suas composições farmacêuticas |
| DK2069335T3 (da) * | 2006-09-08 | 2013-02-18 | Actelion Pharmaceuticals Ltd | Pyridin-3-ylderivater som immunomoduleringsmidler |
| AU2007334436A1 (en) * | 2006-12-15 | 2008-06-26 | Abbott Laboratories | Novel oxadiazole compounds |
| AU2009220893A1 (en) * | 2008-03-07 | 2009-09-11 | Actelion Pharmaceuticals Ltd | Novel aminomethyl benzene derivatives |
| GB0911130D0 (en) * | 2009-06-26 | 2009-08-12 | Glaxo Group Ltd | Novel compounds |
-
2010
- 2010-08-20 TW TW099128025A patent/TW201120016A/zh unknown
- 2010-08-23 UY UY0001032853A patent/UY32853A/es not_active Application Discontinuation
- 2010-08-23 AR ARP100103076A patent/AR077908A1/es unknown
- 2010-08-24 CN CN2010800633803A patent/CN102762102A/zh active Pending
- 2010-08-24 CA CA2783851A patent/CA2783851A1/en not_active Abandoned
- 2010-08-24 MX MX2012006667A patent/MX2012006667A/es not_active Application Discontinuation
- 2010-08-24 WO PCT/US2010/046424 patent/WO2011071570A1/en not_active Ceased
- 2010-08-24 EP EP10836346.6A patent/EP2509424A4/en not_active Withdrawn
- 2010-08-24 JP JP2012543093A patent/JP2013512951A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| MX2012006667A (es) | 2012-10-15 |
| WO2011071570A1 (en) | 2011-06-16 |
| JP2013512951A (ja) | 2013-04-18 |
| CA2783851A1 (en) | 2011-06-16 |
| EP2509424A4 (en) | 2013-09-04 |
| UY32853A (es) | 2011-06-30 |
| TW201120016A (en) | 2011-06-16 |
| EP2509424A1 (en) | 2012-10-17 |
| CN102762102A (zh) | 2012-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR077908A1 (es) | Compuestos de oxadiazol como moduladores de s1p | |
| PE20091712A1 (es) | Derivados de azetidina y ciclobutano como inhibidores de jak | |
| PE20121815A1 (es) | Compuestos de pirrolo-pirimidina como inhibidores de cdk4/6 | |
| ES3034431T3 (en) | Bicyclic heteroaryl derivatives as mnk1 and mnk2 modulators and uses thereof | |
| AR073263A1 (es) | Derivados de piridina y su uso en diagnostico de imagenes mediante pet | |
| PE20151539A1 (es) | Nuevos derivados de pirazol | |
| AR067757A1 (es) | Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales. | |
| AR067090A1 (es) | Espiriciclos como inhibidores de la 11- beta hidroxiesteroide deshidrogenasa de tipo 1 | |
| PE20090060A1 (es) | ANALOGOS DE IMIDAZOLOPIRIMIDINA Y SU USO COMO INHIBIDORES DE PI3 CINASA Y mTOR | |
| PE20120121A1 (es) | Derivados de imidazopirazina como inhibidores de syk | |
| PE20090370A1 (es) | Derivados de heterociclo fusionado como inhibidores de quinasa | |
| AR087288A1 (es) | Compuestos de tetrahidropirido-piridina y tetrahidropirido-pirimidina y su uso como moduladores de receptores de c5a | |
| PE20121025A1 (es) | Compuestos de benzoxazepina como inhibidores de la p13k | |
| PE20060842A1 (es) | Amino-imidazolonas para la inhibicion de b-secretasa | |
| PE20151249A1 (es) | Derivados de pirazolopirimidina como inhibidores de jak quinasas | |
| PE20081159A1 (es) | Inhibidores de las quinasas y metodos para su utilizacion | |
| AR077463A1 (es) | Derivados de imidazo[1, 2 - a]pirazina y su uso en medicamentos para el tratamiento de enfermedades parasitarias | |
| AR076928A1 (es) | Derivados de 3h-pirido[4, 3-d]pirimidin-4-ona, un metodo para su preparacion, composiciones farmaceuticas que los comprenden y su uso en la manufactura de un medicamento para el tratamiento o prevencion de enfermedades relacionadas con el estres. | |
| SV2010003779A (es) | Inhibidores de ciclopropil-polimerasa ref. tipo193 pct/slv/fd/1vh | |
| PE20190339A1 (es) | 1h-pirazolo[4,3-b] piridinas como inhibidores de pde1 | |
| PE20091436A1 (es) | Derivados de sulfonamidas sustituidas como moduladores b1r | |
| RU2013142881A (ru) | Имидазопиразины | |
| ES2530815T3 (es) | Tiazolil y oxazolil-isoquinolinonas y métodos para usar las mismas | |
| AR087212A1 (es) | ANTAGONISTAS DE CRTh2 | |
| RU2016119662A (ru) | ПИРИДАЗИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ RORc |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |